Adherence and retention of female injection drug users in a phase III clinical trial in inner city Baltimore

American Journal of Drug and Alcohol Abuse

Volumn 33, Issue 1, 2007, Pages 71-80

  Semba, Richard D ^a   Ricketts, Erin P ^b   Mehta, Shruti F ^b   Kirk, Gregory D ^b   Latkin, Carl ^b   Galai, Noya ^b   Vlahov, David ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

Adherence; Clinical trial; HCV; HIV; Injection drug user; Minority

Indexed keywords

IRON; METHADONE; MULTIVITAMIN;

ADULT; ARTICLE; CAUCASIAN; CONTROLLED STUDY; EVALUATION; FEMALE; FOLLOW UP; GROUPS BY AGE; HUMAN; INTRAVENOUS DRUG ABUSE; IRON DEFICIENCY ANEMIA; IRON THERAPY; MAJOR CLINICAL STUDY; MEDICAL EXAMINATION; PATIENT ATTITUDE; PATIENT COMPLIANCE; WOMEN'S HEALTH;

ADULT; BALTIMORE; DEMOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C; HIV INFECTIONS; HUMANS; METHADONE; NARCOTICS; PREVALENCE; RETENTION (PSYCHOLOGY); SUBSTANCE ABUSE, INTRAVENOUS; URBAN POPULATION;

EID: 33947231783     PISSN: 00952990     EISSN: 10979891     Source Type: Journal    
DOI: 10.1080/00952990601082696     Document Type: Article

References (27)

1. Allen M. The dilemma of women of color in clinical trials. J Am Med Wom Assoc 1994; 49:105-109.
2. Harris Y, Gorelick PB, Samuels P, Bempong I. Why African Americans may not be participating in clinical trials. J Natl Med Assoc 1996; 88:630-634.
3. Singh N, Squire C, Sivek C, Wagener M, Hong Nguyen M, Yu VL. Determinants of compliance with antiretroviral therapy in patients with human immunodeficiency virus: Prospective assessment with implications for enhancing compliance. AIDS Care 1996; 8:261-269.
4. Singh N, Berman SM, Swindells S, Justis JC, Mohr JA, Squier C, Wagener MM. Adherence of human immunodeficiency virus-infected patients to antiretroviral therapy. Clin Infect Dis 1999; 29:824-830.
5. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999; 131:81-87.
6. Gifford AL, Bormann JE, Shively MJ, Wright BC, Richman DD, Bozzette SA. Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. J Acquir Immune Defic Syndr 2000; 23:386-395.
7. Mabunda-Temple G. Recruitment of African Americans in AIDS clinical trials: Some recommended strategies. ABNF J 1998; 9:61-64.
8. Sengupta S, Strauss RP, DeVellis R, Quinn SC, DeVellis B, Ware WB. Factors affecting African-American participation in AIDS research. J Acquir Immune Defic Syndr 2000; 24:275-284.
9. National Institutes of Health. Fiscal Year 2007: Plan for HIV-Related Research. National Institutes of Health, U.S. Department of Health and Human Services. http://www.nih.gov/od/oar/public/pubs/fy2007 (Accessed March 10, 2006).
10. Craven DE, Liebman HA, Fuller J, Hagerty C, Cooley TP, Saunders CA, Steger KA, Libman H. AIDS in intravenous drug users: Issues related to enrollment in clinical trials. J Acquir Immune Defic Syndr 1990; 3(suppl 2):S45-S50.
11. Murphy TF. Women and drug users: the changing faces of HIV clinical drug trials. Qual Rev Bull 1991; 17:26-32.
12. Cotton DJ, Finkelstein DM, He W, Feinberg J, AIDS Clinical Trials Group. Determinants of accrual of women to a large, multicenter clinical trials program of human immunodeficiency virus infection. J Acquir Immune Defic Syndr 1993; 6:1322-1328.
13. Samet JH, Libman HA, Steger KA, Dhawan RK, Chen J, Shevitz AH, Dewees-Dunk R, Levenson S, Kufe D, Craven DE. Compliancewith zidovudine therapy in patients infected with human immundeficiency virus, type 1: a cross-sectional study in a municipal hospital clinic. Am J Med 1992; 92:495-502.
14. O'Connor PG, Selwyn PA, Schottenfeld RS. Medical care for injection-drug users with human immunodeficiency virus infection. N Engl J Med 1994; 331:450-459.
15. Broers B, Morabia A, Hirschel B. A cohort study of drug users' compliance with zidovudine treatment. Arch Intern Med 1994; 154:1121-1127.
16. Bangsberg DR, Hecht FM, Charlebois ED, Zolopa AR, Holodniy M, Sheiner L, Bamberger JD, Chesney MA, Moss A. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS 2000; 14:357-366.
17. Harrison K, Vlahov D, Jones K, Charron K, Clements ML. Medical eligibility, comprehension of the consent process, and retention of injection drug users recruited for an HIV vaccine trial. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 10:386-390.
18. Freedberg KA, Sullivan L, Georgakis A, Savetsky J, Stone V, Samet JH. Improving participation in HIV clinical trials: impact of a brief intervention. HIV Clin Trials 2001; 2:205-212.
19. Morse EV, Simon PM, Coburn M, Hyslop N, Greenspan D, Balson PM. Determinants of subject compliance within an experimental anti-HIV drug protocol. Soc Sci Med 1991; 32:1161-1167.
20. Messiah A, Navaline H, Davis-Vogel A, Tobin-Fiore D, Metzger D. Sociodemographic and behavioral characteristics associated with timeliness and retention in a 6-month follow-up study of high-risk injection drug users. Am J Epidemiol 2003; 157:93-939.
21. Nelson KE, Vlahov D, Galai N, Astemborski J, Solomon L. Preparations for AIDS vaccine trials. Incident human immunodeficiency virus (HIV) infections in a cohort of injection drug users in Baltimore, Maryland. AIDS Res Hum Retroviruses 1994; 10(suppl 2):S201-S205.
22. Purcell DW, Metsch LR, Latka M, Santibanez S, Gomez CA, Eldred L, Latkin CA, INSPIRE Study Group. Interventions for seropositive injectors - Research and evaluation. An integrated behavioral intervention with HIV-positive injection drug users to address medical care, adherence, and risk reduction. J Acquir Immune Defic Syndr 2004; 37(suppl 2):S110-S118.
23. Cottler LB, Compton WM, Ben-Abdallah A, Horne M, Claverie D. Achieving a 96.6 percent follow-up rate in a longitudinal study of drug abusers. Drug Alcohol Depend 1996; 41:209-217.
24. Des Jarlais DC, Marmor M, Friedmann P, Titus S, Aviles E, Deren S, et al. HIV incidence among injection drug users in New York City, 1992-1997: Evidence for a declining epidemic. Am J Pub Health 2000; 90:352-359.
25. Robles RR, Reyes JC, Colón HM, Sahai H, Marrero DA, Matos TD, Calderon JM, Shepard EW. Effects of combined counseling and case management to reduce HIV risk behaviors among Hispanic drug injectors in Puerto Rico: A randomized controlled study. J Subst Abuse Treat 2004; 27:145-152.
26. Stein MD, Solomon DA, Anderson BJ, Herman DS, Anthony JL, Brown RA, Ramsey SE, Brown RA, Miller IW. Persistence of antidepressant treatment effects in a pharmacotherapy plus psychotherapy trial for active injection drug users. Am J Addict 2005; 14:346-357.
27. Baldwin JA, Bowen AM, Trotter RT. Factors contributing to retention of out-of-treatment drug users in an HIV/AIDS outreach prevention project. Drug Soc 1996; 9:19-36.